We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
ARCA biopharma, Inc., a company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, received Fast Track designation from the FDA for AB201 as a potential treatment for COVID-19.
Pending FDA feedback, ARCA anticipates initiating the Phase 2b portion of a sequential Phase 2b/3 clinical evaluation of AB201 in the fourth quarter of this year.